GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bright Minds Biosciences Inc (NAS:DRUG) » Definitions » Inventories, Raw Materials & Components

Bright Minds Biosciences (Bright Minds Biosciences) Inventories, Raw Materials & Components : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Bright Minds Biosciences Inventories, Raw Materials & Components?

Bright Minds Biosciences's inventories, raw materials & components for the quarter that ended in Mar. 2024 was $0.00 Mil.


Bright Minds Biosciences Inventories, Raw Materials & Components Historical Data

The historical data trend for Bright Minds Biosciences's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bright Minds Biosciences Inventories, Raw Materials & Components Chart

Bright Minds Biosciences Annual Data
Trend Sep20 Sep21 Sep22 Sep23
Inventories, Raw Materials & Components
- - - -

Bright Minds Biosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Bright Minds Biosciences Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


Bright Minds Biosciences (Bright Minds Biosciences) Business Description

Industry
Traded in Other Exchanges
Address
19 Vestry Street, New York, NY, USA, 10013
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.